Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention

Frontiers in Immunology

Immunology

Zicheng Zhu¹  Yixuan Chen¹  Jing Zhang¹  Xiao Liu²  Fuwei Liu³  Jitao Ling⁴  Pingping Yang⁴  Peng Yu⁴  Jianping Liu⁴  Yanlin Yang⁴  Jiayu Zhang⁵  Deju Zhang⁶  Xuejing Ma⁷ 

[1] Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China;Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Cardiology, The Affiliated Ganzhou Hospital of Nanchang University, Jiangxi, China;Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Nanchang, China;Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Nanchang, China;Huankui Academy, Nanchang University, Jiangxi, Nanchang, China;Food and Nutritional Sciences, School of Biological Sciences, The University of Hong Kong, Hong Kong, Hong Kong SAR, China;Xiangya School of Medicine, Central South University, Changsha, China;

关键词: NLRP3;    COVID-19;    SARS-CoV-2;    diabetes;    cytokine storm;   

DOI  :  10.3389/fimmu.2023.1203389

 received in 2023-04-10, accepted in 2023-09-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

2019 Coronavirus Disease (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A “cytokine storm”, i.e., elevated levels of pro-inflammatory cytokines in the bloodstream, has been observed in severe cases of COVID-19. Normally, activation of the nucleotide-binding oligomeric domain-like receptor containing pyrin domain 3 (NLRP3) inflammatory vesicles induces cytokine production as an inflammatory response to viral infection. Recent studies have found an increased severity of necrobiosis infection in diabetic patients, and data from several countries have shown higher morbidity and mortality of necrobiosis in people with chronic metabolic diseases such as diabetes. In addition, COVID-19 may also predispose infected individuals to hyperglycemia. Therefore, in this review, we explore the potential relationship between NLRP3 inflammatory vesicles in diabetes and COVID-19. In contrast, we review the cellular/molecular mechanisms by which SARS-CoV-2 infection activates NLRP3 inflammatory vesicles. Finally, we propose several promising targeted NLRP3 inflammatory vesicle inhibitors with the aim of providing a basis for NLRP3-targeted drugs in diabetes combined with noncoronary pneumonia in the clinical management of patients.

【 授权许可】

Unknown   
Copyright © 2023 Zhang, Ma, Liu, Zhang, Ling, Zhu, Chen, Yang, Yang, Liu, Zhang, Liu and Yu